Patents by Inventor Soeren Berg Padkjaer

Soeren Berg Padkjaer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized anti-human NKG2A monoclonal antibody
    Patent number: 8796427
    Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 5, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Petrus Johannes Louis Spee, Jianhe Chen, Søren Berg Padkjær, Jing Su, Jinchao Zhang, Jiujiu Yu
  • COMPOSITIONS AND METHODS FOR REGULATING NK CELL ACTIVITY
    Publication number: 20140193430
    Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Application
    Filed: December 13, 2013
    Publication date: July 10, 2014
    Applicants: NOVO NORDISK A/S, UNIVERSITY OF GENOA, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: SØREN BERG PADKJAER, ALESSANDRO MORETTA, MARIELLA DELLA CHIESA, PASCALE ANDRE, LAURENT GAUTHIER, PETER ANDREAS NICOLAI RUMERT WAGTMANN
  • Anti-C5a receptor antibodies
    Patent number: 8613926
    Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: December 24, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Kristian Kjaergaard, Soeren Lund, Soeren Berg Padkjaer
  • Humanized Anti-Human NKG2A Monoclonal Antibody
    Publication number: 20110052606
    Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.
    Type: Application
    Filed: January 23, 2009
    Publication date: March 3, 2011
    Inventors: Petrus Johannes Louis Spee, Jianhe Chen, Søren Berg Padkjaer, Jing Su, Jinchao Zhang, Jiujiu Yu
  • Compositions and Methods for Regulating NK Cell Activity
    Publication number: 20100291110
    Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Application
    Filed: June 10, 2010
    Publication date: November 18, 2010
    Applicants: NOVO NORDISK A/S, INNATE PHARMA S.A., UNIVERSITY OF GENOA
    Inventors: Søren Berg Padkjaer, Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Peter Andreas Nicolai Reumert Wagtmann